# Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions

> **NCT03553875** · PHASE3 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 25 (actual)

## Conditions studied

- Autism
- Autism Spectrum Disorder
- Nonverbal Learning Disability

## Interventions

- **DRUG:** Memantine Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03553875
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-13
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** requested by the IRB
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03553875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03553875, "Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03553875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*